Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
94%
Chronic Hepatitis B
58%
Hepatitis B Virus
30%
Tenofovir
20%
Adefovir
19%
Entecavir
19%
Combination Therapy
18%
Lamivudine
15%
Liver Cirrhosis
15%
Overall Survival
13%
Telbivudine
11%
Neoplasm
11%
Somatomedin C
10%
Polyacrylamide Gel Electrophoresis
10%
Tenofovir Disoproxil
9%
Sorafenib
9%
Phosphotransferase
8%
Recurrent Disease
8%
Hepatitis B
8%
Fibrosis
7%
Nonalcoholic Fatty Liver
7%
Fatty Liver
7%
Bacterial Peritonitis
7%
Alcohol Liver Cirrhosis
7%
Portal Vein Thrombosis
7%
Hepatitis B(e) Antigen
7%
Virus DNA
6%
Liver Cancer
6%
Liver Fibrosis
6%
Monotherapy
5%
Antiviral Therapy
5%
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Chronic Hepatitis B
37%
Hepatitis B Virus
17%
Liver Cirrhosis
15%
Overall Survival
14%
Nonalcoholic Fatty Liver
14%
Hazard Ratio
13%
Transcatheter Arterial Chemoembolization
12%
Liver Fibrosis
12%
Fibrosis
11%
Polyacrylamide Gel Electrophoresis
10%
Neoplasm
10%
Entecavir
9%
Antiviral Therapy
9%
Liver Cancer
9%
Recurrent Disease
8%
Cohort Analysis
8%
Chronic Liver Failure
8%
Bilirubin
7%
SOFA Score
7%
Alcohol Liver Disease
7%
Chronic Hepatitis
7%
Fluorodeoxyglucose F 18
7%
Spontaneous Bacterial Peritonitis
7%
Portal Vein Thrombosis
7%
Non-Alcoholic Fatty Liver Disease
7%
Survival Estimate
7%
Colorectal Carcinoma
7%
Cancer Cell
7%
Lamivudine
6%
Virus Reactivation
5%
Recurrence Free Survival
5%
In Vitro
5%
Tenofovir
5%
Positron Emission Tomography-Computed Tomography
5%
Computer Assisted Tomography
5%
Risk Stratification
5%
Carcinoma Cell
5%
Metastatic Carcinoma
5%